Armistice Capital Reports 9.99% Stake in Biodexa Pharmaceuticals Plc

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A regarding their holdings in Biodexa Pharmaceuticals Plc (BDRX). The filing reports that as of March 31, 2026, the reporting persons beneficially own 187,975 American Depositary Shares, representing a 9.99% ownership stake in the company. This reflects a significant increase from a previous reported position of zero shares. Armistice Capital serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to have beneficial ownership. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The master fund retains the right to receive dividends and proceeds from the sale of these securities.